News

Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
FoodNavigator1d
Novo Nordisk triples Wegovy sales beyond US, yet future sales outlook falls
Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...
Yahoo Finance29d
Novo Nordisk outlays $1.09bn to boost GLP-1RA production in Brazil
Novo Nordisk has invested 6.4bn Brazilian reais ... the Montes Claros site is already the largest insulin factory in Latin America. A variety of products will be made at the facility, including ...
Seeking Alpha7d
Novo Nordisk: The Fear Is Overblown
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk ...
The Irish Times2d
Novo Nordisk on the back foot ahead of earnings
Novo Nordisk reports earnings on Wednesday, and for once, Wall Street isn’t holding its breath. Once celebrated for routinely raising guidance, the Danish drugmaker is on the defensive.
The Motley Fool17d
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Shares of Novo Nordisk have sold off as rivals launch competing diabetes and weight loss drugs. Yet, the company continues to capitalize on significant growth of its GLP-1 medications. The stock ...
Morningstar7d
Novo Nordisk A/S (B Shares) ADRhedged
Novo Nordisk A/S (B Shares) ADRhedged has an average Morningstar Sustainability Rating of 3 globes, indicating that the ESG risk of holdings in its portfolio is similar to that of its peers in the ...